Gastrointestinal medications

Psychosomatics

Volumn 48, Issue 1, 2007, Pages 79-85

  Wynn, Gary H ^d   Sandson, Neil B ^a,b,c   Cozza, Kelly L ^d,e  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b SHEPPARD PRATT HEALTH SYSTEM   (United States)

^c Sheppard Pratt Psychopharmacology Consultation Service   (United States)

^d WALTER REED ARMY MEDICAL CENTER   (United States)

^e UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALOSETRON; APREPITANT; BUDESONIDE; CILOSTAZOL; CIMETIDINE; CLOZAPINE; CYTOCHROME P450; CYTOCHROME P450 2C19; DIAZEPAM; DOLASETRON MESILATE; ESOMEPRAZOLE; GASTROINTESTINAL AGENT; GLYCOPROTEIN P; GRANISETRON; HISTAMINE H2 RECEPTOR ANTAGONIST; HYPERICUM PERFORATUM EXTRACT; LANSOPRAZOLE; OMEPRAZOLE; ONDANSETRON; PALONOSETRON; PANTOPRAZOLE; PROGUANIL; PROTON PUMP INHIBITOR; PSYCHOTROPIC AGENT; RABEPRAZOLE; RANITIDINE; SEROTONIN 3 ANTAGONIST; TEGASEROD; TROPISETRON; UNINDEXED DRUG;

DRUG EFFICACY; DRUG METABOLISM; DRUG TOLERABILITY; ENZYME INDUCTION; ENZYME INHIBITION; GASTROINTESTINAL DISEASE; GENETIC VARIABILITY; GENOTYPE; HUMAN; REVIEW; UNSPECIFIED SIDE EFFECT;

EID: 33845978034     PISSN: 00333182     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.psy.48.1.79     Document Type: Article

References (72)

1. Robinson M, Horn J: Clinical pharmacology of proton pump inhibitors. Drugs 2003; 63:2739-2754
2. McColl K, Kennedy P: Proton pump inhibitors: differences emerge in hepatic metabolism. Digest Liv Dis 2002; 34:461-467
3. Andersson T: Pharmacokinetics, metabolism, and interactions of acid pump inhibitors. Clin Pharmacokinet 1996; 31:9-26
4. Chong E, Ensom M: Pharmacogenetics of the proton pump inhibitors: a systematic review. Pharmacother 2003; 23:460-471
5. Klotz U, Schwab M, Treiber G: CYP2C19 polymorphism and proton pump inhibitors. Basic Clin Pharmacol Toxicol 2004; 95:2-8
6. Yu K, Yim D, Cho J, et al: Effect of omeprazole on the pharmacokinetics of moclobemide according to the genetic polymorphism of CYP 2C19. Clin Pharmacol Ther 2001; 69:266-273
7. Yasui-Furukori N, Takahata T, Nakagami T, et al: Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes. Br J Clin Pharmacol 2004; 57:487-494
8. Andersson T: Pharmacokinetics, metabolism, and interactions of acid pump inhibitors. Clin Pharmacokinet 1996; 31:9-26
9. Ko J, Sukhova N, Thacker D, et al: Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. Drug Metab Dispo 1997; 25:853-862
10. Rost K, Fuhr U, Thomsen T, et al: Omeprazole weakly inhibits CYP1A2 activity in man. Int J Clin Pharm Ther 1999; 37:567-574
11. Anderssson T, Lundborg P, Regardh C: Lack of effect of omeprazole treatment on steady-state plasma levels of metoprolol. Eur J Clin Pharm 1991; 40:61-65
12. Sachse R, Ochmann K, Rohde G, et al: The effect of omeprazole pre- and co-treatment on cerivastatin absorption and metabolism in man. Int J Clin Pharm Ther 1998; 36:517-520
13. Wood N, Tan K, Purkins L, et al: Effect of omeprazole on the steady-state pharmacokinetics of voriconazole. Br J Clin Pharmacol 2003; 56:56-61
14. Henry D, Somerville K, Kitchingham G, et al: Propranolol steady-state pharmacokinetics are unaltered by omeprazole. Eur J Clin Pharmacol 1987; 33:369-373
15. Andersson T: Omeprazole drug interaction studies. Clin Pharmacokinet 1991; 21:195-212
16. Dilger K, Zhichang Z, Klotz U: Lack of drug interaction between omeprazole, lansoprazole, pantoprazole, and theophylline. Br J Clin Pharmcol 1999; 48:438-144
17. Mookhoek E, Loonen A: Retrospective evaluation of the effect of omeprazole on clozapine metabolism. Pharm World Sci 2004; 26:180-182
18. Frick A, Kopitz J, Bergemann N: Omeprazole reduces clozapine plasma concentrations. Pharmacopsych 2003; 36:121-123
19. van der Weide J, Steijns LS, van Weelden MJ: The effect of smoking and cytochrome P450 CYP1 A2 genetic polymorphism on clozapine clearance and dose requirement. Pharmacogenetics 2003; 13:169-172
20. Suri A, Branner S: Effect of omeprazole: on the metabolism of cilostazol. Clin Pharmacokinet 1999; 37:S53-S59
21. Funck-Bretano C, Becquemont L, Leneveu A, et al: Inhibition by omeprazole of proguanil metabolism: mechanism of the interaction in vitro and prediction of in-vivo results from the in-vitro experiments. J Pharmacol Exp Ther 1997; 280:730-738
22. Gugler R, Jensen J: Omeprazole inhibits oxidative drug metabolism: studies with diazepam and phenytoin in vivo and 7-ethoxycoumarin in vitro. Gastroenterology 1985; 89:1235-1241
23. Wang L, Zhou G, Zhu B, et al: St. John's, wort induces both cytochrome P450 3A4-catalyzed sulfoxidation and 2C19-dependent hydroxylation of omeprazole. Clin Pharm Ther 2004; 75:191-197
24. Delhotal-Landes B, Petite J, Flouvat B: Clinical pharmacokinetics of lansoprazole. Clin Pharmacokinet 1995; 28:458-470
25. Katsuki H, Hamada A, Nakamura C, et al: Role of CYP 3A4 and CYP 2C19 in the stereoselective metabolism of lansoprazole by human liver microsome. Eur J Clin Pharmacol 2001; 57:709-715
26. Fuchs W, Seenewid R, Klotz V: Lansoprazole does not affect the bioavailability of oral contraceptives. Br J Clin Pharmacol 1994; 38:376-380
27. Karol M, Locke C, Cavanaugh J: Lack of pharmacokinetic interaction between lansoprazole and intravenously-administered phenytoin. J Clin Pharmacol 1999; 39:1283-1289
28. Lefebrve R, Flouvat B, Karolac-Tamisier S, et al: Influence of lansoprazole on diazepam plasma concentrations. Clin Pharmacol Ther 1992; 52:458-463
29. Cavanaugh J, Locke C, Karol M: Lack of interaction of lansoprazole or omeprazole with prednisone. Am J Gastroenterol 1993; 88:1589
30. Dilger K, Zheng Z, Klotz U: Lack of drug interaction between omeprazole, lansoprazole, pantoprazole, and theophylline. Br J Clin Pharmacol 1999; 48:438-444
31. Cavanaugh J, Winters E, Cohen A, et al: Lack of effect of lansoprazole on steady-state warfarin metabolism (abstract). Gastroenterology 1991; 100:A40
32. Gerson L, Triadafilopoulos G: Proton pump inhibitors and their drug interactions: an evidence-based approach. Eur J Gastroenterol Hepatol 2001; 13:611-616
33. Horai Y, Kimura M, Furuie H, et al: Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP 2C19 genotypes. Aliment Pharmacol Ther 2001; 15:793-803
34. Huber R, Hartman M, Bliesath H, et al: Pharmacokinetics of pantoprazole in man. Int J Clin Pharmacol Ther 1996; 34:185-194
35. Fitton A, Wiseman L: Pantoprazole. Drugs 1996; 51:460-482
36. Hartman M, Zech K, Bliesath H, et al: Pantoprazole lacks induction of CYP 1A2 activity in man. Int J Clin Pharmacol Ther 1999; 37:159-164
37. Huber R, Bliesath H, Hartman M, et al: Pantoprazole does not interact with the pharmacokinetics of carbamazepine. Int J Clin Pharmacol Ther 1998; 36:521-524
38. Gugler R, Hartman M, Rudi J, et al: Lack of pharmacokinetic interaction of pantoprazole with diazepam in man. Br J Clin Pharmacol 1996; 42:249-252
39. Bliesath H, Huber R, Steinijans V, et al: Pantoprazole does not interact with nifedipine in man under steady-state conditions. Int J Clin Pharmacol Ther 1996; 34:S81-S85
40. De May C, Meineke I, Steinijans V, et al: Pantoprazole lacks interaction with antipyrine in man, either by inhibition or induction. Int J Clin Pharmacol Ther 1994; 32:98-106
41. Hartman M, Huber R, Bliesath H, et al: Lack of interaction between pantoprazole and digoxin at therapeutic doses in man. Int J Clin Pharmacol Ther 1995; 33:481-485
42. Koch H, Hartman M, Bliesath H, et al: Pantoprazole has no influence on steady-state pharmacokinetics and pharmacodynamics of metoprolol in healthy volunteers. Int J Clin Pharmacol Ther 1996; 34:420-423
43. Bliesath H, Huber R, Steinijans V, et al: Lack of pharmacokinetic interaction between pantoprazole and diclofenac. Int J Clin Pharmacol Ther 1996; 34:152-156
44. Ehrlich A, Fuder H, Hartman M, et al: Lack of pharmacodynamic and pharmacokinetic interaction between pantoprazole and phenprocoumon in man. Eur J Clin Pharmacol 1996; 51:277-281
45. Li X, Andersson T, Ahlstrom M, et al: Comparison of inhibitory effects of the proton-pump inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Disp 2004; 32:821-827
46. Andersson T, Hassan-Alin M, Hasselgran G, et al: Drug interaction studies with esomeprazole, the (S)-isomer of omeprazole. Clin Pharmacokinet 2001; 40:523-537
47. Chung W, Park C, Roh H, et al: Oxidation of ranitidine by flavin-containing monooxygenase and cytochrome P450. Jpn J Pharmacol 2000; 84:213-220
48. Martinez C, Albet C, Agundez J, et al: Comparative in-vitro and in-vivo inhibition of cytochrome P450 CYP 1A2, CYP 2D6, and CYP 3A4 by H2-receptor antagonists. Clin Pharmacol Ther 1999; 65:369-376
49. Leucuta A, Vlase L, Farcau D, et al: Pharmacokinetic interaction study between ranitidine and metoclopramide. Rom J Gastroenterol 2004; 13:211-214
50. Leucuta A, Vlase L, Farcau D, et al: A pharmacokinetic interaction study between omeprazole and the H2-receptor antagonist ranitidine. Drug Metabol Drug Interact 2004; 20:273-281
51. Furuta S, Kamada E, Suzuki T, et al: Inhibition of drug metabolism in human liver microsomes by nizatidine, cimetidine, and omeprazole. Xenobiotica 2001; 31:1-10
52. Janicki PK: Cytochrome P450 2D6 metabolism and 5-hydroxytryptamine type 3 receptor-antagonists for postoperative nausea and vomiting. Med Sci Monit 2005; 11:RA322-328
53. Candiotti K, Birnbach D, Lubarsky D, et al: The impact of pharmacogenomics on postoperative nausea and vomiting. Anesthesiology 2005; 102:543-549
54. Blower P: 5-HT3-receptor antagonists and the cytochrome P450 system: clinical implications. Cancer 2002; 8:405-414
55. Watanabe Y, Nakai H, Hoshiai H: The effect of granisetron on in-vitro metabolism of doxorubicin, irinotecan, and etoposide. Curr Med Res Opin 2005; 21:363-368
56. Stoltz R, Cyong J, Shah A, et al: Pharmacokinetic and safety evaluation of palonosetron, a 5-HT3 receptor-antagonist, in U.S. and Japanese healthy subjects. J Clin Pharmacol 2004; 44:520-531
57. Kaiser R, Sezer O, Papies A, et al: Patient-tailored anti-emetic treatment with 5-HT3 receptor-antagonists according to cytochrome P450 2D6 genotypes. J Clin Oncol 2002; 20:2805-2811
58. Koch K, Corrigan B, Manzo J, et al: Alosetron repeat-dose pharmacokinetics, effects on enzyme activities, and influence of demographic factors. Aliment Pharmacol Ther 2004; 20:223-230
59. D'Souza D, Levasseur L, Nezamis J, et al: Effect of alosetron on the pharmacokinetics of alprazolam. J Clin Pharmacol 2001; 41:452-454
60. D'Souza D, Dimmitt D, Robbins D, et al: Effect of alosetron on the pharmacokinetics of fluoxetine. J Clin Pharmacol 2001; 41:451-458
61. Koch K, Ricci B, Hedayetullah N, et al: Effect of alosetron on theophylline pharmacokinetics. Br J Clin Pharmacol 2001; 52:596-600
62. Koch K, Campanella C, Baidoo C, et al: Pharmacodynamics and pharmacokinetics of oral contraceptives co-administered with alosetron (Lotronex). Dig Dis Sci 2004; 49:1244-1249
63. Sanchez R, Wang R, Newton D, et al: Cytochrome P450 3A4 is the major enzyme involved in the metabolism of the substance-P receptor-antagonist Aprepitant. Drug Metab Disp 2004; 32:1287-1292
64. Majumdar A, McCrea J, Panebianco D, et al: Effects of A prepitant on cytochrome P450 3A4 activity using midazolam as a probe. Clin Pharmacol Ther 2003; 74:150-156
65. Shadle C, Lee Y, Majumdar A, et al: Evaluation of potential inductive effects of Aprepitant on cytochrome P450 3A4 and 2C9 activity. J Clin Pharmacol 2004; 44:215-233
66. Edsbacker S, Andersson T: Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn's disease. Clin Pharmacokinet 2004; 43:803-821
67. Meloche C, Sharma V, Swedmark S, et al: Sulfation of budesonide by the human cytosolic sulfotransferase, dehydroepiandrosteronesulfotransferase (DHEA-ST). Drug Metab Disp 2002; 30:582-585
68. Schwab M, Klotz U: Pharmacokinetic considerations in the treatment of inflammatory bowel disease. Clin Pharmacokinet 2001; 40:723-751
69. Seidegard J: Reduction of the inhibitory effect of ketoconazole on budesonide pharmacokinetics by separation of their time of administration. Clin Pharmacol Ther 2000; 67:13-17
70. Raaska K, Niemi M, Neuvonen M, et al: Plasma concentrations of inhaled budesonide and their effects on plasma cortisol are increased by the P450 3A4-inhibitor itraconazole. Clin Pharmacol Ther 2002; 72:362-369
71. Zhou H, Horowitz A, Ledford P, et al: The effects of tegaserod (HTF 919) on the pharmacokinetics and pharmacodynamics of digoxin in healthy subjects. J Clin Pharmacol 2001; 41:1131-1139
72. Appel-Dingemanse S: Clinical pharmacokinetics of tegaserod, a serotonin 5-HT4 receptor partial agonist with promotile activity. Clin Pharmacokinet 2002; 41:1021-1042